Showing 681-690 of 1066 results for "".
Clinical Trials for Huntington Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/clinical-trials-for-huntington-disease/31681/The promise for potential disease-modifying research is strong, although continued discovery uncovers new questions and challenges to overcome.Evaluating Heterogeneous Treatment Effects in Pursuit of Personalized Multiple Sclerosis Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/evaluating-heterogeneous-treatment-effects-in-pursuit-of-personalized-multiple-sclerosis-care/33141/Heterogeneous treatment effect methodologies can be used to enhance individualized care for people with multiple sclerosis.Muscle MRI for Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/muscle-mri-for-neuromuscular-disorders/31687/Using muscle MRI to diagnose neuromuscular conditions requires awareness of different patterns of muscle involvement.Team Approach: Enhancing Collaboration in AAD Management
https://practicalneurology.com/programs/cme/team-approach-enhancing-collaboration-in-aad-management/27097/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Therapeutic Approaches to Neuromuscular Repeat Disorders: Facioscapulohumeral Muscular Dystrophy and Myotonic Dystrophy Type 1
https://practicalneurology.com/diseases-diagnoses/neuromuscular/therapeutic-approaches-to-neuromuscular-repeat-disorders-facioscapulohumeral-muscular-dystrophy-and-myotonic-dystrophy-type-1/32027/A promising pipeline of therapeutics target toxic RNA.Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Special Report: Cognitive Screening After COVID-19
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/special-report-cognitive-screening-after-covid-19/31791/Tools are needed for the assessment of neurologic and neuropsychologic sequelae of infection with the SARS-CoV-2 virus.Health Care Disparities in Alzheimer Disease Diagnosis and the Use of Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/health-care-disparities-in-alzheimer-disease-diagnosis-and-the-use-of-amyloid-targeting-treatments/36240/Disparities in Alzheimer disease care persist, and people from underrepresented racial, ethnic, or socioeconomic groups face considerable barriers to early diagnosis and access to disease-modifying anti-amyloid therapies.Practical Recommendations for Monitoring Response to Amyloid-Targeting Treatments for Early Alzheimer Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/practical-recommendations-for-monitoring-response-to-amyloid-targeting-treatments-for-early-alzheimer-disease/36189/The authors present practical recommendations for using cognitive assessments and amyloid PET scanning to monitor response to amyloid-targeting treatments in clinical practice.Pharmacologic Considerations in the Treatment of Older Adults With Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pharmacologic-considerations-in-the-treatment-of-older-adults-with-epilepsy/32176/Many antiseizure medications are available for treatment of older adults with epilepsy, and choosing the best option requires understanding of their pharmacokinetic and pharmacodynamic properties.